Xia Zhanga,
Zhi-qing Zhanga,
Li-cang Zhanga,
Ke-xin Wanga,
Lan-tong Zhang
b and
De-qiang Li
*a
aDepartment of Pharmacy, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, P. R. China. E-mail: deqli@163.com; Tel: +86 0311-66636302 Tel: +86 18132685779
bDepartment of Pharmaceutical Analysis, School of Pharmacy, Hebei Medical University, P. R. China
First published on 28th July 2021
Buddleja lindleyana Fort., a traditional Chinese medicine, has demonstrated anti-inflammatory, immunomodulatory, antidementia, neuroprotective, antibacterial, and antioxidant effects. Its flowers, leaves, and roots have been used as traditional Chinese medicines. A simple and rapid high-performance liquid chromatography method coupled with mass spectrometry (HPLC-MS/MS) was applied in the multicomponent determination of Buddleja lindleyana Fort., and the discrepancies in the contents from ten different habitats were analyzed. The present study simultaneously determined the concentrations of seven chemical compounds of Buddleja lindleyana Fort. extract in rat plasma via HPLC-MS/MS, which was applied in the pharmacokinetic (PK) study of Buddleja lindleyana Fort. A C18 column was used for chromatographic separation, and ion acquisition was achieved by multiple-reaction monitoring (MRM) in negative ionization mode. The optimized mass transition ion-pairs (m/z) for quantization were 591.5/282.8 for linarin, 609.4/300.2 for rutin, 284.9/133.0 for luteolin, 300.6/151.0 for quercetin, 268.8/116.9 for apigenin, 283.0/267.9 for acacetin, 623.3/160.7 for acteoside, and 252.2/155.8 for sulfamethoxazole (IS). A double peak appeared in the drug–time curve of apigenin, which was associated with entero-hepatic recirculation. There were discrepancies in the contents of seven chemical compounds from 10 batches of Buddleja lindleyana Fort., which were associated with the growth environments. Herein, the pharmacokinetic parameters of seven analytes in Buddleja lindleyana Fort. extract are summarized. The maximum plasma concentration (Cmax) of linarin, rutin, luteolin, quercetin, apigenin, acacetin and acteoside were 894.12 ± 9.34 ng mL−1, 130.76 ± 18.33 ng mL−1, 77.37 ± 25.72 ng mL−1, 20.15 ± 24.85 ng mL−1, 146.42 ± 14.88 ng mL−1, 31.92 ± 17.58 ng mL−1, and 649.78 ± 16.42 ng mL−1, respectively. The time to reach Cmax for linarin, rutin, luteolin, quercetin, apigenin, acacetin, and acteoside were 10, 5, 5, 5, 180, 10 and 10 min, respectively. This is the first report on the simultaneous determination of seven active components for 10 different growing environments and the pharmacokinetic studies of seven active components in rat plasma after the oral administration of Buddleja lindleyana Fort. extract. This study lays the foundation for a better understanding of the absorption mechanism of Buddleja lindleyana Fort., and the evaluation of its clinical application.
In recent years, high-performance liquid chromatography coupled with mass spectrometry (HPLC-MS/MS) has been routinely used to determine the contents of chemical compounds in traditional chemical materials and also applied in pharmacokinetic studies in rats and humans.15,16 Moreover, it has been used to study drug metabolism,17–22 toxicokinetics,23,24 lipidomics,25,26 proteomics27,28 and metabolomics.29,30 The main advantage of mass spectrometry (MS/MS) is the ability to detect a broad range of drugs with high sensitivity and specificity in a single analytical run.31–34 Chemical compounds are recognized by comparing their retention times and parent-daughter ions with those of reference substances.
Pharmacokinetics (PK) is a discipline that quantitatively studies the absorption, distribution, metabolism and excretion in vivo, which uses mathematical theory and methods to make an exposition of the law for changing drug concentrations in blood over time. With the development of medicinal chemistry and the continuous improvement of human health, the requirements for the PK of drugs are getting higher and higher, which will determine the development trends of drugs, especially in the foreground of the market. The therapeutic effects of a drug must be strong, with few side effects and good PK parameters.
The contents of chemical compounds (linarin, luteolin, acacia-7-O-β-D-glucopyranoside, acacetin, rutin, quercetin, apigenin, clinoposaponin III, desrhamnoverbascosaponin and mimengoside I) were determined by HPLC and UPLC according to previous research.5,35,36 In this study, a sensitive and rapid HPLC-MS/MS method was developed for the simultaneous determination of seven compounds in different batches of medicinal materials and in rat plasma after oral treatment with Buddleja lindleyana Fort. extract. The HPLC-MS/MS technology demonstrated the advantages of being rapid and efficient. This is the first systematic multicomponent quantification and PK study of seven chemical constituents of Buddleja lindleyana Fort. Multiple-reaction monitoring (MRM) was employed and the ESI source was operated in negative mode. The contents of seven components of Buddleja lindleyana Fort. from ten different sources were compared and the PK parameters were summarized. These results laid the foundation for clinical application.
HPLC-grade methanol was purchased from J. T. Baker Chemical Company (Phillipsburg, NJ, USA). Formic acid (HPLC grade) was provided by Diamond Technology (Dikma Technologies Inc., Lake Forest, CA, USA). Ethanol (analytical grade) was provided by Tianjin Guangfu Technology Development Co. Ltd (Tianjin, China). Purified water was obtained from Guangzhou Watson's Food & Beverage Co. Ltd (Guangzhou, China).
The entire Buddleja lindleyana Fort. plant was collected from Anguo Chinese Medicinal Materials Wholesale Market and identified by Zengke Kong, Professor of Pharmacognosy, Hebei Province Institute for Drug Control. The sources of Buddleja lindleyana Fort. are listed in Table 1.
Sample number | Source |
---|---|
1 | Guangxi |
2 | Xizang |
3 | Sichuan |
4 | Anhui-Bozhou |
5 | Zhejiang-Huzhou |
6 | Yunnan |
7 | Anhui-Bengbu |
8 | Zhejiang-Hangzhou |
9 | Jiangxi |
10 | Henan |
Negative electrospray ionization mode was used for detecting analytes by API 4000+ MS. The following MS/MS conditions were used: ion spray voltage, −4.5 kV; the turbo spray temperature, 550 °C. Nitrogen was used as the nebulizer and auxiliary gas. Furthermore, the flows of the nebulizer gas (gas 1), heater gas (gas 2) and curtain gas were set to 55, 50, and 25 psi, respectively. The declustering potential (DP) and collision energy (CE) of all analytes are summarized in Fig. 1.
For pharmacokinetics study, Buddleja lindleyana Fort. (Xizang) was cut up and soaked for 12 h with 70% ethyl alcohol.37 The ratios of medicinal materials and 70% ethyl alcohol were 1:
15, 1
:
10 and 1
:
10, respectively. The medicinal materials were extracted three times by heating under reflux. The extraction solutions were filtered and merged, and were concentrated by reducing the pressure. Finally, the residuary solution was concentrated to get the Buddleja lindleyana Fort. extract with a concentration equivalent to 2.5 g mL−1 of the raw Buddleja lindleyana Fort. material. The content of linarin, rutin, luteolin, quercetin, apigenin, acacetin and acteoside were 14
828.24, 422.1, 510.99, 336.45, 665.01, 1840.24 and 1555.87 ng mL−1, respectively. For the PK study, Buddleja lindleyana Fort. (Xizang) was treated with this method.
For the PK study, the mixed standard solution was made by mixing the seven stock solutions, which contained 2894.93 ng mL−1 of linarin, 410.28 ng mL−1 of rutin, 248.68 ng mL−1 of luteolin, 65.52 ng mL−1 of quercetin, 467.72 ng mL−1 of apigenin, 104.68 ng mL−1 of acacetin and 2077.28 ng mL−1 of acteoside. A series of standard mixture working solutions with concentrations in the range of 6.85–14474.65 ng mL−1 for linarin, 6.05–2051.40 ng mL−1 for rutin, 7.90–1243.40 ng mL−1 for luteolin, 6.60–327.60 ng mL−1 for quercetin, 8.85–2338.60 ng mL−1 for apigenin, 11.60–523.40 ng mL−1 for acacetin, and 10.15–10
386.40 ng mL−1 for acteoside, were obtained by the attenuation of stock standard solutions with methanol. The concentration of the IS (sulfamethoxazole) standard solution was 1.18 μg mL−1, which was dissolved in methanol.
Working solutions of the corresponding concentrations (20 μL) and IS solution (20 μL) were added to 100 μL of blank rat plasma. The ranges of the final plasma concentrations were 1.37–2894.93 ng mL−1 for linarin, 1.21–410.28 ng mL−1 for rutin, 1.58–248.68 ng mL−1 for luteolin, 1.32–65.52 ng mL−1 for quercetin, 1.77–467.72 ng mL−1 for apigenin, 2.32–104.68 ng mL−1 for acacetin, and 2.03–2077.28 ng mL−1 for acteoside.
The quality control (QC) samples containing low, medium and high concentrations were prepared at the concentrations of 6.85, 723.73 and 2861.18 ng mL−1 for linarin, 6.05, 102.57 and 418.53 ng mL−1 for rutin, 6.32, 62.17 and 247.58 ng mL−1 for luteolin, 2.64, 16.38 and 64.48 ng mL−1 for quercetin, 7.08, 116.93 and 468.54 ng mL−1 for apigenin, 4.62, 26.17 and 102.14 ng mL−1 for acacetin, 2.03, 519.32 and 2027.29 ng mL−1 for acteoside.
In order to investigate the stability of the samples, they were analyzed at 0, 2, 4, 8, 12, and 24 h at room temperature, respectively.
The RSD values of precision and stability were not more than 5%.
The lower limit of quantification (LLOQ, S/N = 10) of the assay served as the lowest concentration of the standard curve.42 The LLOQ should be less than 10–5% of Cmax. The accuracy of six samples continuously determined should be 80–120%, and the RSD values should be less than 20%.
SE = (measured value − actual value)/actual value × 100% |
RSD = SD/X × 100%; SD = Sqr (∑Xn − X)2/(n − 1) (SD – standard deviation; X – mean; n – number of samples) |
The intra- and inter-day RSD of high and medium concentrations were less than 15%, and the intra- and inter-day RSD of the low concentration was less than 20%. The RE of high and medium concentrations were less than ±15%, and the low concentration was not more than ±20%.
A non-compartmental model was used to calculate the pharmacokinetic parameters of analytes by using the DAS 3.0 software.44,45 The PK parameters calculated in this study included the maximum concentration (Cmax), time of achieving maximum concentration (Tmax), half-time (T1/2), area of the concentration–time curve at 0–24 h (AUC0–t), area of the concentration–time curve at 0–∞(AUC0–∞) and clearance rate (CL), which were expressed as mean ± standard deviation (mean ± SD).
Different mobile phases (methanol–water and acetonitrile–water) were compared in order to obtain a better peak shape and shorter elution time, which showed that the effect of using acetonitrile–water as the mobile phase was better. Moreover, different concentrations of formic acid (0.1%, 0.2%, 0.5%, 0.01%, 0.02% and 0.05%) were compared. Finally, acetonitrile–water (0.1% formic acid) was chosen as the mobile phase in this study.
Component | Regression equation | r | Linear range/(μg mL−1) | LOD (ng mL−1) | LOQ (ng mL−1) |
---|---|---|---|---|---|
Linarin | Y = 1999X + 5742 | 0.999 8 | 10.24–655.38 | 0.40 | 1.30 |
Rutin | Y = 14![]() |
0.999 4 | 0.01875–2.360 | 0.37 | 1.02 |
Luteolin | Y = 14![]() ![]() |
0.999 7 | 0.02625–26.75 | 0.27 | 0.96 |
Quercetin | Y = 29![]() |
0.999 8 | 0.003875–2.47 | 0.38 | 1.00 |
Apigenin | Y = 30![]() ![]() |
0.999 5 | 0.02625–13.62 | 0.34 | 1.02 |
Acacetin | Y = 11![]() ![]() |
0.999 4 | 1.400–212.2 | 0.32 | 0.74 |
Acteoside | Y = 32![]() ![]() |
0.999 6 | 2.750–352.5 | 0.27 | 0.66 |
Analyte | Precision (n = 6) | Accuracy (n = 3) | ||||||
---|---|---|---|---|---|---|---|---|
Intra-day RSD (%) | Inter-day RSD (%) | Stability (%) | Original quantity (μg) | Spiked quantity (μg) | Detected (μg) | Recovery (%) | RSD (%) | |
Linarin | 1.82 | 2.39 | 2.19 | 9536.98 | 7629.24 | 17![]() |
99.67 | 1.09 |
9536.55 | 18![]() |
98.54 | 0.98 | |||||
11![]() |
20![]() |
99.38 | 0.82 | |||||
Rutin | 1.03 | 3.39 | 3.02 | 30.38 | 24.29 | 54.53 | 99.43 | 0.79 |
30.36 | 60.31 | 98.57 | 0.48 | |||||
36.44 | 66.85 | 100.1 | 1.17 | |||||
Luteolin | 1.79 | 2.94 | 1.55 | 260.52 | 208.35 | 466.23 | 98.73 | 0.56 |
260.44 | 520.41 | 99.79 | 0.64 | |||||
312.52 | 569.67 | 98.92 | 0.39 | |||||
Quercetin | 0.56 | 1.75 | 3.68 | 7.24 | 5.79 | 13.12 | 101.5 | 0.84 |
7.24 | 14.34 | 98.02 | 1.03 | |||||
8.69 | 15.86 | 99.26 | 0.98 | |||||
Apigenin | 2.17 | 3.88 | 3.79 | 218.59 | 174.86 | 391.79 | 99.05 | 0.67 |
218.57 | 438.92 | 100.8 | 1.13 | |||||
262.29 | 476.82 | 98.45 | 0.78 | |||||
Acacetin | 1.98 | 4.01 | 4.02 | 4113.61 | 3290.89 | 7380.15 | 99.26 | 1.27 |
4113.61 | 8187.73 | 99.04 | 1.31 | |||||
4936.34 | 9049.95 | 100.0 | 0.59 | |||||
Acteoside | 1.64 | 3.22 | 2.37 | 1179.68 | 943.75 | 2105.59 | 98.11 | 0.46 |
1179.69 | 2356.54 | 99.76 | 0.63 | |||||
1415.62 | 2580.44 | 98.95 | 0.86 |
Content (μg g−1,n = 3) | Linarin | Rutin | Luteolin | Quercetin | Apigenin | Acacetin | Acteoside |
---|---|---|---|---|---|---|---|
1 | 6581.903 | 15.080 | 79.359 | 2.563 | 12.660 | 2091.259 | 837.118 |
2 | 9536.981 | 30.377 | 260.522 | 7.238 | 218.592 | 4113.609 | 1179.681 |
3 | 7967.634 | 47.280 | 134.832 | 11.376 | 104.280 | 2705.533 | 3268.070 |
4 | 6962.231 | 16.364 | 167.611 | 36.405 | 67.599 | 2907.661 | 673.124 |
5 | 7700.850 | 19.088 | 462.755 | 2.710 | 120.592 | 2625.502 | 999.367 |
6 | 5341.558 | 6.743 | 1.071 | 0.825 | 2.441 | 1530.265 | 445.744 |
7 | 5363.830 | 6.263 | 1.723 | 0.525 | 2.690 | 102.032 | 981.599 |
8 | 5713.082 | 23.612 | 14.470 | 1.842 | 21.240 | 645.446 | 6949.254 |
9 | 5908.544 | 13.550 | 28.033 | 0.898 | 63.274 | 879.504 | 1571.813 |
10 | 6529.122 | 8.779 | 54.185 | 0.440 | 35.725 | 413.231 | 606.707 |
Cluster analysis was performed for Buddleja lindleyana Fort. from ten habitats, as displayed in Fig. 2. The results showed that Buddleja lindleyana Fort. from ten habitats were divided into five classes (Class I: 1, 4 and 5; Class II: 6, 7, 9 and 10, Class III: 2, Class IV: 3 and Class V: 8). Buddleja lindleyana Fort. from Tibet (Xizang) was used as an extract for intragastric administration to perform the PK study. Buddleja lindleyana Fort. material from Xizang was selected as the representative plant for pharmacokinetic study because of its highest content of the main compounds. The results revealed that the contents of compounds in Buddleja lindleyana Fort. were associated with their places of origin and planting environments, which would guide the safety and rationalization of clinical use of traditional Chinese medicine.
Analyte | Regression equation | R2 | Linear range (ng mL−1) | LLOQ (ng mL−1) |
---|---|---|---|---|
Linarin | Y = 0.0008X + 0.0034 | 0.9998 | 1.37–2894.93 | 1.37 |
Rutin | Y = 0.0024X + 0.0001 | 0.9989 | 1.21–410.28 | 1.21 |
Luteolin | Y = 0.2120X + 0.1311 | 0.9979 | 1.58–248.68 | 1.58 |
Quercetin | Y = 0.0259X + 0.0007 | 0.9974 | 1.32–65.52 | 1.32 |
Apigenin | Y = 0.0085X + 0.0002 | 0.9981 | 1.77–467.72 | 1.77 |
Acacetin | Y = 0.0545X + 0.0232 | 0.9978 | 2.32–104.68 | 2.32 |
Acteoside | Y = 0.0166X − 0.0056 | 0.9989 | 2.03–2077.28 | 2.03 |
Compounds spiked concentration (ng mL−1) | Intra-day (n = 6) | Inter-day (n = 6) | ||||
---|---|---|---|---|---|---|
Measured concentration (ng mL−1) | Accuracy (%) | Precision (%) | Measured concentration (ng mL−1) | Accuracy (%) | Precision (%) | |
Linarin | ||||||
6.85 | 6.97 ± 1.78 | 1.75 | 8.19 | 7.05 ± 3.36 | 2.92 | 4.57 |
723.73 | 735.74 ± 3.45 | 1.66 | 5.04 | 736.68 ± 4.34 | 1.79 | 3.19 |
2861.18 | 2969.33 ± 5.86 | 3.78 | 7.93 | 2958.17 ± 2.01 | 3.39 | 4.86 |
![]() |
||||||
Rutin | ||||||
6.05 | 6.20 ± 4.24 | 2.48 | 3.47 | 6.15 ± 6.19 | 1.65 | 3.67 |
102.57 | 106.55 ± 5.83 | 3.88 | 6.23 | 105.08 ± 7.42 | 2.45 | 8.25 |
418.53 | 424.81 ± 9.09 | 1.50 | 5.01 | 438.12 ± 4.89 | 4.68 | 5.62 |
![]() |
||||||
Luteolin | ||||||
6.32 | 6.60 ± 1.07 | 4.43 | 9.16 | 6.69 ± 6.09 | 5.85 | 7.47 |
62.17 | 64.11 ± 3.33 | 3.12 | 7.31 | 64.27 ± 5.12 | 3.38 | 4.85 |
247.58 | 252.68 ± 4.47 | 2.06 | 6.04 | 253.40 ± 8.48 | 2.35 | 5.79 |
![]() |
||||||
Quercetin | ||||||
2.64 | 2.79 ± 3.14 | 5.68 | 6.85 | 2.78 ± 7.04 | 5.30 | 8.74 |
16.38 | 16.84 ± 4.57 | 2.81 | 4.16 | 17.14 ± 6.46 | 4.64 | 7.88 |
64.48 | 65.38 ± 6.81 | 1.40 | 3.58 | 68.70 ± 8.43 | 6.54 | 6.89 |
![]() |
||||||
Apigenin | ||||||
7.08 | 7.27 ± 4.13 | 2.68 | 5.75 | 7.41 ± 6.44 | 4.66 | 4.69 |
116.93 | 121.70 ± 3.49 | 4.08 | 5.89 | 123.76 ± 8.66 | 5.84 | 6.59 |
468.54 | 485.55 ± 5.23 | 3.63 | 7.51 | 480.49 ± 5.18 | 2.55 | 5.86 |
![]() |
||||||
Acacetin | ||||||
4.62 | 4.71 ± 3.15 | 1.95 | 7.48 | 4.93 ± 7.14 | 6.71 | 6.46 |
26.17 | 27.24 ± 4.65 | 4.09 | 4.46 | 27.14 ± 4.68 | 3.71 | 4.61 |
102.14 | 105.46 ± 7.65 | 3.25 | 5.17 | 107.08 ± 6.23 | 4.84 | 3.83 |
![]() |
||||||
Acteoside | ||||||
2.03 | 2.14 ± 8.18 | 5.42 | 5.58 | 2.13 ± 8.02 | 4.93 | 5.79 |
519.32 | 536.20 ± 7.54 | 3.25 | 4.52 | 564.14 ± 9.98 | 8.63 | 7.98 |
2027.29 | 2167.78 ± 6.25 | 1.39 | 6.93 | 2100.48 ± 5.24 | 3.61 | 8.75 |
Compounds spiked concentration (ng mL−1) | Short-tern stability (room temperature for 8 h) | Long-tern stability (−20 °C for 21 d) | Free-thaw stability (3 free thaw cycles) | Post-preparation stability (room temperature for 4 h) | ||||
---|---|---|---|---|---|---|---|---|
Measured concentration (ng mL−1) | Accuracy (%) | Measured concentration (ng mL−1) | Accuracy (%) | Measured concentration (ng mL−1) | Accuracy (%) | Measured concentration (ng mL−1) | Accuracy (%) | |
Linarin | ||||||||
6.85 | 7.07 ± 1.76 | 3.21 | 7.10 ± 17.48 | 3.65 | 7.02 ± 0.73 | 2.48 | 7.22 ± 1.36 | 5.40 |
723.73 | 755.28 ± 10.77 | 4.36 | 766.72 ± 17.29 | 5.94 | 754.99 ± 16.54 | 4.32 | 740.38 ± 7.66 | 2.30 |
2861.18 | 2930.71 ± 17.78 | 2.43 | 3056.88 ± 21.55 | 6.84 | 2962.18 ± 18.46 | 3.53 | 2986.21 ± 12.59 | 4.37 |
![]() |
||||||||
Rutin | ||||||||
6.05 | 6.36 ± 6.81 | 5.12 | 6.31 ± 5.88 | 4.30 | 6.2 ± 1.88 | 2.48 | 6.26 ± 0.48 | 3.47 |
102.57 | 108.48 ± 7.41 | 5.76 | 107.37 ± 9.98 | 4.68 | 110.30 ± 8.24 | 7.54 | 106.61 ± 13.32 | 3.94 |
418.53 | 426.82 ± 18.15 | 1.98 | 429.20 ± 19.79 | 2.55 | 437.7 ± 10.02 | 4.58 | 440.50 ± 16.46 | 5.25 |
![]() |
||||||||
Luteolin | ||||||||
6.32 | 6.76 ± 0.18 | 6.96 | 6.7 ± 0.76 | 6.01 | 6.60 ± 0.18 | 4.43 | 6.50 ± 0.16 | 2.85 |
62.17 | 64.88 ± 0.92 | 4.36 | 67.34 ± 3.63 | 8.32 | 66.03 ± 2.64 | 6.21 | 64.29 ± 0.37 | 3.41 |
247.58 | 260.55 ± 0.49 | 5.24 | 261.02 ± 4.65 | 5.43 | 258.35 ± 4.86 | 4.35 | 253.42 ± 2.77 | 2.36 |
![]() |
||||||||
Quercetin | ||||||||
2.64 | 2.80 ± 1.62 | 6.06 | 2.72 ± 0.32 | 3.03 | 2.78 ± 0.89 | 5.30 | 2.74 ± 0.32 | 3.79 |
16.38 | 17.12 ± 1.22 | 4.52 | 17.27 ± 2.69 | 5.43 | 17.48 ± 1.19 | 6.72 | 16.78 ± 1.77 | 2.44 |
64.48 | 66.98 ± 7.47 | 3.88 | 68.36 ± 3.68 | 6.02 | 67.46 ± 2.42 | 4.62 | 66.99 ± 4.58 | 3.89 |
![]() |
||||||||
Apigenin | ||||||||
7.08 | 7.17 ± 1.91 | 1.27 | 7.58 ± 0.51 | 7.06 | 7.34 ± 0.32 | 3.67 | 7.33 ± 0.16 | 3.53 |
116.93 | 123.78 ± 2.47 | 5.86 | 124.51 ± 4.02 | 6.48 | 124.68 ± 6.33 | 6.63 | 122.61 ± 7.12 | 4.86 |
468.54 | 490.89 ± 7.31 | 4.77 | 484.98 ± 5.09 | 3.51 | 494.36 ± 4.99 | 5.51 | 485.92 ± 3.94 | 3.71 |
![]() |
||||||||
Acacetin | ||||||||
4.62 | 4.69 ± 0.36 | 1.52 | 4.81 ± 0.27 | 4.11 | 4.81 ± 0.22 | 4.11 | 4.78 ± 0.18 | 3.46 |
26.17 | 27.31 ± 5.34 | 4.36 | 26.53 ± 3.21 | 1.38 | 26.99 ± 4.36 | 3.13 | 27.25 ± 3.96 | 4.13 |
102.14 | 107.02 ± 3.38 | 4.78 | 105.68 ± 9.65 | 3.46 | 108.48 ± 6.51 | 6.21 | 107.29 ± 6.25 | 5.04 |
![]() |
||||||||
Acteoside | ||||||||
2.03 | 2.11 ± 0.13 | 3.94 | 2.07 ± 0.12 | 1.97 | 2.1 ± 0.14 | 3.45 | 2.16 ± 0.35 | 6.40 |
519.32 | 548.82 ± 2.92 | 5.68 | 540.92 ± 9.44 | 4.16 | 544.87 ± 4.54 | 4.92 | 542.64 ± 4.56 | 4.49 |
2027.29 | 2150.14 ± 11.92 | 6.06 | 2167.98 ± 18.52 | 6.94 | 2132.91 ± 11.91 | 5.21 | 2140.01 ± 9.32 | 5.56 |
Compounds spiked concentration (ng mL−1) | Extraction recovery | Matrix effect | ||
---|---|---|---|---|
Mean (%) | RSD (%) | Mean (%) | RSD (%) | |
Linarin | ||||
6.85 | 89.02 | 3.16 | 80.67 | 3.67 |
723.73 | 85.42 | 5.94 | 85.34 | 7.97 |
2861.18 | 87.57 | 2.95 | 91.27 | 4.45 |
![]() |
||||
Rutin | ||||
6.05 | 87.68 | 2.86 | 101.5 | 3.65 |
102.57 | 88.75 | 5.64 | 95.10 | 4.18 |
418.53 | 86.76 | 3.53 | 90.13 | 5.29 |
![]() |
||||
Luteolin | ||||
6.32 | 83.43 | 4.42 | 83.56 | 3.13 |
62.17 | 96.21 | 6.57 | 85.86 | 6.71 |
247.58 | 88.84 | 7.32 | 87.47 | 7.16 |
![]() |
||||
Quercetin | ||||
2.64 | 87.39 | 2.64 | 96.49 | 5.48 |
16.38 | 88.64 | 4.89 | 88.77 | 4.23 |
64.48 | 90.05 | 7.13 | 97.64 | 6.26 |
![]() |
||||
Apigenin | ||||
7.08 | 89.77 | 2.39 | 101.2 | 5.87 |
116.93 | 87.16 | 3.42 | 93.28 | 2.16 |
468.54 | 96.89 | 4.08 | 90.09 | 1.93 |
![]() |
||||
Acacetin | ||||
4.62 | 85.48 | 4.42 | 84.07 | 2,67 |
26.17 | 89.66 | 7.21 | 87.59 | 5.26 |
102.14 | 84.06 | 2.95 | 91.28 | 4.98 |
![]() |
||||
Acteoside | ||||
2.03 | 89.10 | 3.95 | 87.31 | 5.18 |
519.32 | 90.69 | 4.78 | 84.23 | 7.34 |
2027.29 | 85.25 | 5.23 | 90.79 | 5.87 |
![]() |
||||
Sulfamethoxazole (IS) | ||||
476 | 98.41 | 3.78 | 95.67 | 3.28 |
Compounds | Cmax (ng mL−1) (mean ± SD) | Tmax (min) | T1/2 (min) | AUC0–t (ng L−1 h−1) (mean ± SD) | AUC0–∞ (ng L−1 h−1) (mean ± SD) | CL (L h−1 kg−1) |
---|---|---|---|---|---|---|
Linarin | 894.12 ± 9.34 | 10 ± 0.45 | 36.49 ± 0.07 | 28![]() |
28![]() |
695.164 |
Rutin | 130.76 ± 18.33 | 5 ± 0.35 | 49.57 ± 0.18 | 3039.40 ± 26.08 | 3039.62 ± 54.07 | 6464.93 |
Luteolin | 77.37 ± 25.72 | 5 ± 0.41 | 36.08 ± 0.24 | 2106.15 ± 28.81 | 2122.72 ± 34.23 | 9421.89 |
Quercetin | 20.15 ± 24.85 | 5 ± 0.33 | 46.03 ± 0.09 | 558.58 ± 33.33 | 1093.45 ± 55.91 | 18![]() |
Apigenin | 146.42 ± 14.88 | 180 ± 0.38 | 298.50 ± 0.16 | 85![]() |
85![]() |
233.21 |
Acacetin | 31.92 ± 17.58 | 10 ± 0.35 | 96.87 ± 0.12 | 916.00 ± 51.59 | 1062.19 ± 50.61 | 18![]() |
Acteoside | 649.78 ± 16.42 | 10 ± 0.22 | 46.80 ± 0.35 | 18![]() |
18![]() |
1069.26 |
The results showed that the mean plasma concentration–time curves of the seven compounds were made up of two parts, which included (A) linarin, rutin, luteolin, quercetin, acacetin and acteoside and (B) apigenin. Linarin, rutin, luteolin, quercetin, acacetin and acteoside were rapidly absorbed, and the Tmax values were 10, 5, 5, 5, 10 and 10 min, respectively. However, the Tmax of apigenin was 180 min. The T1/2 of the seven chemical compounds were 36.49, 49.57, 36.08, 46.03, 298.50, 96.87 and 46.80 min.
The concentrations of linarin and acteoside were highest. Acteoside could be obtained by the hydrolysis of linarin after oral administration of Buddleja lindleyana Fort. extract, which indicated that the amount of acteoside absorbed in blood included the chemical compound acteoside and part of the hydrolysed linarin. A further study should be performed, such as on the metabolism and excretion of the linarin monomer. A double-peak phenomenon of apigenin appeared in Fig. 4, which was associated with entero-hepatic recirculation. The first peak of apigenin appeared at 5 min, and the second at 180 min, which is higher than the first. In general, the results of this study might be helpful for the study of metabolism, excretion and activity screening after oral administration of Buddleja lindleyana Fort. extract and monomer linarin, which would be beneficial for the application of Buddleja lindleyana Fort. in clinical therapy.
Footnote |
† Electronic supplementary information (ESI) available: The validation information on the content analysis. Table repeatability and matrix effect of seven analytes. See DOI: 10.1039/d1ra04154a |
This journal is © The Royal Society of Chemistry 2021 |